Baleares

ANTI-CLL1 SINGLE-DOMAIN ANTIBODY AND USE THEREOF

Resumen de: AU2022489190A1

The present invention relates to an anti-CLL1 single-domain antibody and use thereof. Specifically, the present invention relates to a single-domain antibody having an amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can specifically target a CLL1-positive cell, and can be applied to the detection of CLL1 expression in bone marrow cells of AML patients. The single-domain antibody can be prepared into a specific antibody drug clinically used for preventing and treating CLL1 target-related diseases (such as acute myeloid leukemia, myelodysplastic syndromes, or chronic myeloid leukemia), and can also be used for preparing CAR cells targeting CLL1, a detection kit for a CLL1 protein, or the like. The single-domain antibody drug is stable in structure, small in molecule, easy to recombinantly express, and low in production cost, and can be used alone or as a drug loading system to carry related drugs, which has very wide prospects and important significance in the fields of drug application, clinical diagnosis, and the like.

MEDICAMENT FOR TREATING HUMAN TUMOR BASED ON ERF3A-TARGETING PROTEOLYSIS MECHANISM

Resumen de: US2025213701A1

The present disclosure provides a proteolysis-targeting compound TPB-L-E3B, a method for synthesizing the same, and use thereof. The compound can treat human tumor diseases through the eRF3a-targeting proteolysis mechanism, and exhibits great potential in treating such diseases in in-vitro studies, particularly, in treating diseases such as prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer, and the like.

METHODS FOR TREATING LYMPHOMA

Resumen de: US2025213562A1

Compositions and methods for treating lymphoma, in particular. T-cell lymphoma and follicular lymphoma. in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.

METHODS FOR IDENTIFYING RESISTANCE OR RESPONSE TO VENETOCLAX/HYPOMETHYLATING AGENT/ANTI-CD70 AGENT TREATMENT FOR ACUTE MYELOID LEUKEMIA

Resumen de: AU2023390486A1

The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsiveness to AML treatment regimens, including regimens comprising the administration of a BCL-2 inhibitor, a hypomethylating agent, a CD70-targeting agent, or any combination thereof, the methods comprising identifying the presence or absence of one or more biomarkers described herein.

POLYNUCLEOTIDE, CHIMERIC ANTIGEN RECEPTOR, VECTOR, COMPOSITION, METHOD FOR PRODUCING A MODIFIED IMMUNE EFFECTOR CELL AND USE OF THE POLYNUCLEOTIDE

Resumen de: WO2025137751A1

The present invention relates to a polynucleotide encoding an anti-BCMA chimeric antigen receptor (CAR) and to the polypeptide corresponding to the anti-BCMA chimeric antigen receptor (CAR) itself. The present invention also relates to a vector and a composition, comprising an immune effector cell, comprising the polynucleotide, as well as a method for producing the modified immune effector cell and the use of the polynucleotide, the vector, the composition or the immune effector cell produced by the method for the manufacture of a drug for the treatment of multiple myeloma.

NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER

Resumen de: US2025216392A1

Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38′ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CD38 protein.

METHODS OF TREATING AML BY IDENTIFYING AND TARGETING A MYELOID/LYMPHOID LEUKEMIA STEM CELL

Resumen de: AU2023390484A1

The present disclosure provides methods of treating acute myeloid leukemia (AML) and methods of determining responsiveness to AML treatment regimens, the methods comprising identifying the presence or absence of Myeloid/Lymphoid leukemia stem cells (M/L LSC) in a sample from a subject.

DETERMINING A PATIENT’S RESPONSE TO A TREATMENT IN MULTIPLE MYELOMA

Resumen de: US2025213185A1

The present disclosure relates to a computer-implemented method of a computer-implemented method of determining a patient's response to a treatment in multiple myeloma. The method comprises:providing results of a series of predefined consecutive tests on the patient,determining a response at time t as a function of a test result of the time t and a subsequent test result of a time t+1.

ANTI-CD86 CAR EXPRESSING LYMPHOCYTES FOR TARGETED TUMOR THERAPY

Resumen de: AU2024213852A1

New PCT-application based on EP 23 154 047.7 Ludwig-Maximilians-Universität München, Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt Vossius Ref.: AF3867 PCT S3The present invention relates to the recognition of CD86 as a marker of hematological cancer and thus relates to CD86 targeting agents for the treatment of such cancers, in particular, acute myeloid leukemia (AML), Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). The invention in particular encompasses a lymphocyte recombinantly expressing a chimeric antigen T cell receptor (CAR) comprising an antigen binding domain that specifically binds CD86 for use in the treatment of such cancers, as well as also encompassing the CAR construct, i.e., comprising an antigen binding domain that specifically binds CD86.

CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND CXCR5

Resumen de: AU2025204455A1

- 55 - The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CXCR5, preferably pathogenic mature B cells and/or memory B cells, and/or pathogenic T cells and/or T follicular helper cells, in particular mature B cell non-Hodgkin’s lymphoma (B-NHL), T cell non-Hodgkin's lymphoma, or autoantibody-dependent autoimmune disease, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis. - 55 The invention relates to an isolated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen-binding domain, comprising an antibody or antibody fragment that binds a human CXC chemokine receptor type 5 (CXCR5) protein. The invention further relates to a nucleic acid molecule encoding the CAR of the invention, a genetically modified immune cell, preferably a T cell, expressing the CAR of the invention and the use of said cell in the treatment of a medical disorder associated with the presence of pathogenic cells expressing C

PHARMACEUTICAL COMPOSITION

Resumen de: WO2025140579A1

The present application relates to a pharmaceutical composition, comprising an active ingredient compound 1, a pharmaceutically acceptable polymer carrier, a surfactant and other pharmaceutically acceptable excipients, wherein the active ingredient, the polymer carrier and optionally at least a portion of the surfactant are present in the form of a solid dispersion. Disclosed in the present application is the pharmaceutical composition containing the compound 1 for the first time. The composition has stable product quality and good bioavailability. On the basis of the characteristic that the compound 1 is a JAK inhibitor, the composition has wide application prospects for alopecia areata, vitiligo, atopic dermatitis, psoriasis, membranous nephropathy, ankylosing spondylitis, peripheral T cell lymphoma, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, etc.

PHARMACEUTICAL COMPOSITION OF ANAPLASTIC LYMPHOMA KINASE INHIBITOR AND PREPARATION METHOD THEREFOR

Resumen de: WO2025140560A1

A pharmaceutical composition of a polycyclic anaplastic lymphoma kinase inhibitor, a preparation method therefor, and use thereof. In particular, the present disclosure relates to a pharmaceutical preparation of 5-chloro-N4-(2-(isopropylsulfonyl)phenyl)-N2-(7-methyl-8-(piperidin-4-yl)-2,3-dihydrobenzob1,4dioxin-5-yl)pyrimidine-2,4-diamine, a preparation method therefor, and use thereof.

CIRCULAR RNA ENCODING CARS AND THE USE THEREOF

Resumen de: WO2025139121A1

Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.

METHODS OF TREATING CHRONIC MYELOID LEUKEMIA USING THE TYROSINE KINASE INHIBITOR VODOBATINIB

Resumen de: AU2023331249A1

The present invention relates to methods of treating leukemia using Tyrosine Kinase inhibitors. The invention particularly relates to methods of treating CML and ALL using a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of Formula 1 has been shown to be efficacious safe and tolerable at a dose from 10 mg to 210 mg.

COMPOSITION FOR AMPLIFYING FLT3 GENE, AND USES THEREOF

Resumen de: EP4578962A1

The present invention relates to a composition for amplifying a FLT3 gene, and uses thereof, and, more particularly, to a composition comprising a primer set capable of simultaneously amplifying an ITD detection region and a TKD mutation region of the FLT3 gene, and uses thereof. The composition for gene amplification, according to the present invention, enables the simultaneous performance of: diagnosis of acute myeloid leukemia (AML) in patients having FLT3-ITD mutations; determination of targeted anticancer treatment prescription for AML patients having FLT3-ITD mutations; detection of minimal residual disease (MRD) in AML patients; prognosis prediction in AML patients; and identification of drug resistance to AML tyrosine kinase inhibitors, and thus, shortens the time to derive analysis results from samples and enables efficient testing. The present invention enables the selection of correct and rapid diagnosis and treatment methods in the treatment of patients with acute myeloid leukemia, and thus is useful for early treatment and recurrence prevention.

Pharmaceutical combination for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma

Resumen de: WO2024102361A1

A pharmaceutical combination includes a beta-lactam antibiotic alone or in combination with a beta-lactamase inhibitor useful for treating multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. A method for treating multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma includes administering to a patient in need thereof an effective amount of a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor. Beta-lactam antibiotic for use in combination with a beta-lactamase inhibitor for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, or smoldering multiple myeloma in a patient in need of the treatment is also described.

Methods of treating non-hodgkin lymphoma

Resumen de: AU2023373683A1

Methods of treating non-Hodgkin lymphoma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.

Peptides and combinations of peptides for use in immunotherapy against acute myeloid leukemia (aml) and other hematological neoplasms

Resumen de: AU2023376971A1

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

KIT FOR BIOLOGICAL MATERIAL SAMPLING AND PRE-ANALYTICAL PROCESSING

Resumen de: BG113823A

The object of the present invention is the creation of a ready-to-use individual kit (kit) for sampling biological material such as blood or bone marrow and its unified pre-analytical processing, for subsequent measurement of minimal residual disease by multi-parameter flow cytometry including supra-parametric DNA staining. The finished kit aims to facilitate, speed up and standardize the processes of collection and subsequent preparation of individual blood or bone marrow samples from patients diagnosed with acute or chronic B-cell lymphoid leukemia, for subsequent highly specialized flow cytometric analysis, the results of which can be used as an objective criterion to assess and monitor therapeutic response. Advantages of the proposed kit are: it is standardized, preventing unconscious omissions in proper use; it contains everything needed in one space to perform the manipulation and the simultaneous pre-analytical preparation, even by persons with minimal knowledge in the field; it considerably shortens the time from sample collection to processing and, thus, provides optimal conditions for preserving the qualities of the cells in the sample and reducing cell detritus, which is very important for the subsequent analysis; compact - contains everything you need in one package with two compartments that can be manipulated separately without compromising the integrity of the other; includes a 7-color panel with all essential B-cell markers, as well as supernatant DNA staining

Pharmaceutical formulations of Bruton's tyrosine kinase inhibitor

Resumen de: AU2025204331A1

PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazolo 3,4-dpyrimidin- l-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. PHARMACEUTICAL FORMULATIONS OF BRUTON'S TYROSINE KINASE INHIBITOR Abstract Formulation A Formulation B Formulation C Formulation D 0 6 12 18 24 Nominal Time Post-Dose (h) Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor I-((R)-3-(4-amino-3-(4-phenoxyphenyl)-IH-pyrazole 3,4-dpyrimidin- 1-yl)piperidin-l-yl)prop-2-en-I-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. un ' u n b s t r a c t o r m u l a t i o n o r m u l a t i o n Mean Ibrutinib Plasma Concentration (ng/mL) o r m u l a t i o n o r m u l a t i o n o m i n a l i m e o s t - o s e ( h ) e s c r i b e d h e r e i n a r e p h a r m a c e u t i c a l f o r m u l a t i o n s o f r u t o n ' s t y r o s i n e k i n a s e (

DOSING FOR COMBINATION TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-CD79B ANTIBODY DRUG CONJUGATE

Resumen de: US2025206835A1

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.

METHODS FOR DETECTING CELLULAR TRANSITIONS

Resumen de: WO2025137363A1

The disclosure relates, inter alia, to methods for monitoring cellular transitions associated with or indicative of a presence or a stage of a myelodysplastic syndrome-related disease.

miRNA500 T Pharmaceutical composition for preventing or treating T cell lymphoma comprising miRNA500 inhibitor

Resumen de: KR20250095509A

본 발명은 miRNA500 억제제를 포함하는 T세포 림프종의 예방 또는 치료용 약제학적 조성물에 관한 것으로, 본 발명의 miRNA500 억제제를 포함하는 T세포 림프종의 예방 또는 치료용 약제학적 조성물은 miRNA500의 발현, 기능 또는 활성을 억제 또는 하향 조절하여 T세포 림프종에 대한 항종양 활성을 나타내므로, T세포 림프종의 예방 또는 치료 용도로 유용하게 이용될 수 있다.

REPURPOSING VARENICLINE AS AN ANTI-INFLAMMATORY AGENT WITH ITS SUPPRESSOR EFFECTS ON INFLAMMATORY CYTOKINES

Resumen de: US2025205248A1

A method of a clinical use of varenicline apart from a smoking cessation is provided, including supressing inflammatory cytokines with the varenicline and repositioning the varenicline as an anti-inflammatory drug. The varenicline is repositioned in an LPS-induced in-vitro inflammation model by using a commercially available and widely used immortalized macrophage cell line obtained from male adult Balb/c mice and transformed by Abelson murine leukemia virus.

TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 FOR THE TREATMENT OF MULTIPLE MYELOMA

Nº publicación: WO2025134050A1 26/06/2025

Solicitante:

JANSSEN BIOTECH INC [US]
JANSSEN BIOTECH, INC